RE-109
Pharmaceutical compound
From Wikipedia, the free encyclopedia
O-Glutarylpsilocin (developmental code name RE109), also known as 4-glutaryloxy-N,N-dimethyltryptamine (4-HO-DMT O-glutarate or 4-GO-DMT) is a serotonergic psychedelic of the tryptamine family.[1][2] It acts as a prodrug of psilocin (4-HO-DMT) similarly to other psilocin prodrugs like 4-AcO-DMT, 4-PrO-DMT, and psilocybin (4-PO-DMT).[1][2] The drug is cleaved into psilocin by non-specific esterases.[1][2] O-Glutarylpsilocin was first described in the scientific literature in 2024.[1][2] It has been patented by Reunion Neuroscience.[2] A related drug, luvesilocin (RE-104, FT-104; 4-GO-DiPT), a prodrug of 4-HO-DiPT, is being developed for potential medical use.[1][2]
Other namesPsilocin glutarate; Psilocin O-glutarate; RE109; RE-109; 4-Glutaryloxy-N,N-dimethyltryptamine; 4-HO-DMT O-glutarate; 4-GO-DMT; DMT-4-glutarate
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
FormulaC17H22N2O4
| Clinical data | |
|---|---|
| Other names | Psilocin glutarate; Psilocin O-glutarate; RE109; RE-109; 4-Glutaryloxy-N,N-dimethyltryptamine; 4-HO-DMT O-glutarate; 4-GO-DMT; DMT-4-glutarate |
| Drug class | Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C17H22N2O4 |
| Molar mass | 318.373 g·mol−1 |
| 3D model (JSmol) | |
| |
| |